Answers are grounded in this paper and cite their sources.
In vitro study shows PLL-g-PEG polymer reduces antibody-drug conjugate uptake in human corneal epithelial cells, suggesting a potential strategy to prevent ocular toxicity.
Antibody-drug conjugates (ADCs) are a relatively recent advance in the delivery of chemotherapeutics that improve targeting of cytotoxic agents. However, despite their antitumor activity, severe ocular adverse effects, including vision loss, have been reported for several ADCs. The nonspecific uptake of ADCs into human corneal epithelial cells (HCECs) and their precursors via macropinocytosis has been proposed to be the primary mechanism of ocular toxicity. In this study, we evaluated the ability of a novel polymer, poly(l-lysine)-graft-poly(ethylene glycol) (PLL-g-PEG), to decrease the ADC rituximab-mc monomethylauristatin F (MMAF) (RIX) uptake into human corneal epithelial (HCE-T) cells.
No takes yet. Share an insight, caveat, or question.
Kleinman et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: